Project Number: 8042-32000-107-03-T
Project Type: Trust Fund Cooperative Agreement
Start Date: Jan 1, 2013
End Date: Dec 30, 2017
SEPPIC is an adjuvant company which sells various adjuvants (agent that boost immunity) for vaccine formulation for humans, livestock, poultry, and fish. The major objective of this study is to investigate commercially available SEPPIC's adjuvants for their immune boosting effect on the immunization of broiler chickens using Clostridium perfringens proteins. ARS will use necrotic enteritis (NE) disease model that was developed by ARS to evaluate the effects of adjuvant-protein formulations and to study immune mechanisms. Investigate effects of different antibiotic alternatives on coccidian parasites. Study basic immune mechanisms that are associated with enhanced innate immunity.
SEPPIC's commercially available adjuvants will be mixed with Clostridium and coccidia proteins at ARS and injected orally or subcutaneously to broiler chickens. Immune parameters to be assessed include serum and intestinal antibodies, lymphocyte proliferation and cytokine response as well as gut lesions and body weights. Conduct in vivo trials using Eimeria profilin and Eimeria EF1 antigens as spray formulation for coccidiosis challenge. Seppic’s Montanide Gel will be used in spray vaccination. For IL-7 as adjuvant, we will use biologically active proteins as well.